CCS Publications  2015-2016

  • Zucchetto, A., Tissino, E., Hartmann, T.N., Chigaev, A., Del Poeta, G., Colombatti, A., and Gattei, V. (2016). Ibrutinib Inhibits VLA-4-Dependent Adhesion in CLL-Letter. Clin Cancer Res 22, 3410-3411.

  • Zuber, V., Marconett, C.N., Shi, J., Hua, X., Wheeler, W., Yang, C., Song, L., Dale, A.M., Laplana, M., Risch, A., Witoelar, A., Thompson, W.K., Schork, A.J., Bettella, F., Wang, Y., Djurovic, S., Zhou, B., Borok, Z., van der Heijden, H.F., de Graaf, J., Swinkels, D., Aben, K.K., McKay, J., Hung, R.J., Bikeboller, H., Stevens, V.L., Albanes, D., Caporaso, N.E., Han, Y., Wei, Y., Panadero, M.A., Mayordomo, J.I., Christiani, D.C., Kiemeney, L., Andreassen, O.A., Houlston, R., Amos, C.I., Chatterjee, N., Laird-Offringa, I.A., Mills, I.G., and Landi, M.T. (2016). Pleiotropic Analysis of Lung Cancer and Blood Triglycerides. Journal of the National Cancer Institute 108.

  • Zimmermann, F.A., Neureiter, D., Feichtinger, R.G., Trost, A., Sperl, W., Kofler, B., and Mayr, J.A. (2016). Deficiency of respiratory chain complex I in Hashimoto thyroiditis. Mitochondrion 26, 1-6.

  • Zielinski, C., Lang, I., Inbar, M., Kahan, Z., Greil, R., Beslija, S., Stemmer, S.M., Zvirbule, Z., Steger, G.G., Melichar, B., Pienkowski, T., Sirbu, D., Petruzelka, L., Eniu, A., Nisenbaum, B., Dank, M., Anghel, R., Messinger, D., Brodowicz, T., and investigators, T. (2016). Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial. The Lancet Oncology 17, 1230-1239.

  • Zelle-Rieser, C., Thangavadivel, S., Biedermann, R., Brunner, A., Stoitzner, P., Willenbacher, E., Greil, R., and Johrer, K. (2016). T cells in multiple myeloma display features of exhaustion and senescence at the tumor site. J Hematol Oncol 9, 116.

  • Zaborsky, N., Gassner, F.J., Asslaber, D., Reinthaler, P., Denk, U., Flenady, S., Hofbauer, J.P., Danner, B., Rebhandl, S., Harrer, A., Geisberger, R., Greil, R., and Egle, A. (2016). CD1d expression on chronic lymphocytic leukemia B cells affects disease progression and induces T cell skewing in CD8 positive and CD4CD8 double negative T cells. Oncotarget 7, 49459-49469.

  • Yuan, H., Liu, H., Liu, Z., Owzar, K., Han, Y., Su, L., Wei, Y., Hung, R.J., McLaughlin, J., Brhane, Y., Brennan, P., Bickeboeller, H., Rosenberger, A., Houlston, R.S., Caporaso, N., Landi, M.T., Heinrich, J., Risch, A., Christiani, D.C., Gumus, Z.H., Klein, R.J., Amos, C.I., and Wei, Q. (2016). A Novel Genetic Variant in Long Non-coding RNA Gene NEXN-AS1 is Associated with Risk of Lung Cancer. Sci Rep 6, 34234.

  • Wolkerstorfer, S., Schwaiger, E., Rinnerthaler, M., Karina Gratz, I., Zoegg, T., Brandstetter, H., and Achatz-Straussberger, G. (2016). HAX1 deletion impairs BCR internalization and leads to delayed BCR-mediated apoptosis. Cell Mol Immunol 13, 451-461.

  • Willenbacher, W., Thangavadivel, S., Greil, R., Willenbacher, E., Weger, R., Manzl, C., Johrer, K., and Brunner, A. (2016). Low Beclin-1 expression predicts improved overall survival in patients treated with immunomodulatory drugs for multiple myeloma and identifies autophagy inhibition as a promising potentially druggable new therapeutic target: an analysis from The Austrian Myeloma Registry (AMR). Leukemia & lymphoma 57, 2330-2341.

  • Weiss, L., Huemer, F., Mlineritsch, B., and Greil, R. (2016). Immune checkpoint blockade in ovarian cancer. Memo 9, 82-84.

  • Urbas, R., Mayr, C., Klieser, E., Fuereder, J., Bach, D., Stattner, S., Primavesi, F., Jaeger, T., Stanzer, S., Ress, A.L., Loffelberger, M., Wagner, A., Berr, F., Ritter, M., Pichler, M., Neureiter, D., and Kiesslich, T. (2016). Relevance of MicroRNA200 Family and MicroRNA205 for Epithelial to Mesenchymal Transition and Clinical Outcome in Biliary Tract Cancer Patients. International journal of molecular sciences 17.

  • Troppan, K.T., Melchardt, T., Wenzl, K., Schlick, K., Deutsch, A., Bullock, M.D., Reitz, D., Beham-Schmid, C., Weiss, L., Neureiter, D., Trankenschuh, W., Greil, R., Neumeister, P., Egle, A., and Pichler, M. (2016). The clinical significance of fibrinogen plasma levels in patients with diffuse large B cell lymphoma. J Clin Pathol 69, 326-330.

  • Thangavadivel, S., Zelle-Rieser, C., Olivier, A., Postert, B., Untergasser, G., Kern, J., Brunner, A., Gunsilius, E., Biedermann, R., Hajek, R., Pour, L., Willenbacher, W., Greil, R., and Johrer, K. (2016). CCR10/CCL27 crosstalk contributes to failure of proteasome-inhibitors in multiple myeloma. Oncotarget 7, 78605-78618.

  • Tegtmeyer, N., Moodley, Y., Yamaoka, Y., Pernitzsch, S.R., Schmidt, V., Traverso, F.R., Schmidt, T.P., Rad, R., Yeoh, K.G., Bow, H., Torres, J., Gerhard, M., Schneider, G., Wessler, S., and Backert, S. (2016). Characterisation of worldwide Helicobacter pylori strains reveals genetic conservation and essentiality of serine protease HtrA. Mol Microbiol 99, 925-944.

  • Shi, J., Hua, X., Zhu, B., Ravichandran, S., Wang, M., Nguyen, C., Brodie, S.A., Palleschi, A., Alloisio, M., Pariscenti, G., Jones, K., Zhou, W., Bouk, A.J., Boland, J., Hicks, B., Risch, A., Bennett, H., Luke, B.T., Song, L., Duan, J., Liu, P., Kohno, T., Chen, Q., Meerzaman, D., Marconett, C., Laird-Offringa, I., Mills, I., Caporaso, N.E., Gail, M.H., Pesatori, A.C., Consonni, D., Bertazzi, P.A., Chanock, S.J., and Landi, M.T. (2016). Somatic Genomics and Clinical Features of Lung Adenocarcinoma: A Retrospective Study. PLoS Med 13, e1002162.

  • Shatirishvili, M., Burk, A.S., Franz, C.M., Pace, G., Kastilan, T., Breuhahn, K., Hinterseer, E., Dierich, A., Bakiri, L., Wagner, E.F., Ponta, H., Hartmann, T.N., Tanaka, M., and Orian-Rousseau, V. (2016). Epidermal-specific deletion of CD44 reveals a function in keratinocytes in response to mechanical stress. Cell Death Dis 7, e2461.

  • Schmidt, T.P., Perna, A.M., Fugmann, T., Bohm, M., Jan, H., Haller, S., Gotz, C., Tegtmeyer, N., Hoy, B., Rau, T.T., Neri, D., Backert, S., Schneider, G., and Wessler, S. (2016a). Identification of E-cadherin signature motifs functioning as cleavage sites for Helicobacter pylori HtrA. Sci Rep 6, 23264.

  • Schmidt, T.P., Goetz, C., Huemer, M., Schneider, G., and Wessler, S. (2016b). Calcium binding protects E-cadherin from cleavage by Helicobacter pylori HtrA. Gut pathogens 8, 29.

  • Schafer, S., Salcher, S., Seiter, M., Ranninger, C., Most, M., Obexer, P., Huber, C.G., Ausserlechner, M.J., Schwaiger, S., and Stuppner, H. (2016). Characterization of the XIAP-Inhibiting Proanthocyanidin Fraction of the Aerial Parts of Ephedra sinica. Planta Med 82, 973-985.

  • Rinnerthaler, G., Hackl, H., Gampenrieder, S.P., Hamacher, F., Hufnagl, C., Hauser-Kronberger, C., Zehentmayr, F., Fastner, G., Sedlmayer, F., Mlineritsch, B., and Greil, R. (2016). miR-16-5p Is a Stably-Expressed Housekeeping MicroRNA in Breast Cancer Tissues from Primary Tumors and from Metastatic Sites. International journal of molecular sciences 17.

  • Rawstron, A.C., Fazi, C., Agathangelidis, A., Villamor, N., Letestu, R., Nomdedeu, J., Palacio, C., Stehlikova, O., Kreuzer, K.A., Liptrot, S., O'Brien, D., de Tute, R.M., Marinov, I., Hauwel, M., Spacek, M., Dobber, J., Kater, A.P., Gambell, P., Soosapilla, A., Lozanski, G., Brachtl, G., Lin, K., Boysen, J., Hanson, C., Jorgensen, J.L., Stetler-Stevenson, M., Yuan, C., Broome, H.E., Rassenti, L., Craig, F., Delgado, J., Moreno, C., Bosch, F., Egle, A., Doubek, M., Pospisilova, S., Mulligan, S., Westerman, D., Sanders, C.M., Emerson, R., Robins, H.S., Kirsch, I., Shanafelt, T., Pettitt, A., Kipps, T.J., Wierda, W.G., Cymbalista, F., Hallek, M., Hillmen, P., Montserrat, E., and Ghia, P. (2016). A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study. Leukemia 30, 929-936.

  • Ranninger, C., Schmidt, L.E., Rurik, M., Limonciel, A., Jennings, P., Kohlbacher, O., and Huber, C.G. (2016). Improving global feature detectabilities through scan range splitting for untargeted metabolomics by high-performance liquid chromatography-Orbitrap mass spectrometry. Anal Chim Acta 930, 13-22.

  • Rachar, V., Czejka, M., Kitzmueller, M., Buchner, P., Lichtneckert, M., Greil, R., Geiler, H., and Dittrich, C. (2016). Assessment of Pharmacokinetic Interaction Between Capecitabine and Cetuximab in Metastatic Colorectal Cancer Patients. Anticancer research 36, 4715-4723.

  • Prochazka, K.T., Melchardt, T., Posch, F., Schlick, K., Deutsch, A., Beham-Schmid, C., Weiss, L., Gary, T., Neureiter, D., Klieser, E., Greil, R., Neumeister, P., Egle, A., and Pichler, M. (2016). NCCN-IPI score-independent prognostic potential of pretreatment uric acid levels for clinical outcome of diffuse large B-cell lymphoma patients. British journal of cancer 115, 1264-1272.

  • Pleyer, L., Valent, P., and Greil, R. (2016a). Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis-Masters of Survival and Clonality? International journal of molecular sciences 17.

  • Pleyer, L., Burgstaller, S., Stauder, R., Girschikofsky, M., Sill, H., Schlick, K., Thaler, J., Halter, B., Machherndl-Spandl, S., Zebisch, A., Pichler, A., Pfeilstocker, M., Autzinger, E.M., Lang, A., Geissler, K., Voskova, D., Geissler, D., Sperr, W.R., Hojas, S., Rogulj, I.M., Andel, J., and Greil, R. (2016b). Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications. J Hematol Oncol 9, 39.

  • Pikija, S., Pilz, G., Gschwandtner, G., Rosler, C., Schlick, K., Greil, R., and Sellner, J. (2016). Panitumumab-Associated Encephalopathy after Accidental Intra-arterial Application through Dislocated Central Venous Access Device. Front Neurol 7, 196.

  • Patel, Y.M., Park, S.L., Han, Y., Wilkens, L.R., Bickeboller, H., Rosenberger, A., Caporaso, N., Landi, M.T., Bruske, I., Risch, A., Wei, Y., Christiani, D.C., Brennan, P., Houlston, R., McKay, J., McLaughlin, J., Hung, R., Murphy, S., Stram, D.O., Amos, C., and Le Marchand, L. (2016). Novel Association of Genetic Markers Affecting CYP2A6 Activity and Lung Cancer Risk. Cancer research 76, 5768-5776.

  • Nivarthi, H., Gordziel, C., Themanns, M., Kramer, N., Eberl, M., Rabe, B., Schlederer, M., Rose-John, S., Knosel, T., Kenner, L., Freund, P., Aberger, F., Han, X., Kralovics, R., Dolznig, H., Jennek, S., Friedrich, K., and Moriggl, R. (2016). The ratio of STAT1 to STAT3 expression is a determinant of colorectal cancer growth. Oncotarget 7, 51096-51106.

  • Muller, A.T., Kaymaz, A.C., Gabernet, G., Posselt, G., Wessler, S., Hiss, J.A., and Schneider, G. (2016). Sparse Neural Network Models of Antimicrobial Peptide-Activity Relationships. Mol Inform 35, 606-614.

  • Morath, I., Hartmann, T.N., and Orian-Rousseau, V. (2016). CD44: More than a mere stem cell marker. Int J Biochem Cell Biol 81, 166-173.

  • Melchardt, T., Hufnagl, C., Weinstock, D.M., Kopp, N., Neureiter, D., Trankenschuh, W., Hackl, H., Weiss, L., Rinnerthaler, G., Hartmann, T.N., Greil, R., Weigert, O., and Egle, A. (2016). Clonal evolution in relapsed and refractory diffuse large B-cell lymphoma is characterized by high dynamics of subclones. Oncotarget 7, 51494-51502.

  • Mayr, C., Wagner, A., Loeffelberger, M., Bruckner, D., Jakab, M., Berr, F., Di Fazio, P., Ocker, M., Neureiter, D., Pichler, M., and Kiesslich, T. (2016a). The BMI1 inhibitor PTC-209 is a potential compound to halt cellular growth in biliary tract cancer cells. Oncotarget 7, 745-758.

  • Mayr, C., Beyreis, M., Wagner, A., Pichler, M., Neureiter, D., and Kiesslich, T. (2016b). Deregulated MicroRNAs in Biliary Tract Cancer: Functional Targets and Potential Biomarkers. Biomed Res Int 2016, 4805270.

  • Magnes, T., Melchardt, T., Weiss, L., Hufnagl, C., Greil, R., and Egle, A. (2016). Fluorouracil and Dihydropyrimidine Dehydrogenase Genotyping. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 34, 2433-2434.

  • Leleu, X., Terpos, E., Sanz, R.G., Cooney, J., O'Gorman, P., Minarik, J., Greil, R., Williams, C., Gray, D., and Szabo, Z. (2016). An international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide + dexamethasone for relapsed or relapsed/refractory multiple myeloma (RR-MM). Am J Hematol 91, 806-811.

  • Kristensen, L.H., Olsen, O.H., Blouse, G.E., and Brandstetter, H. (2016). Releasing the brakes in coagulation Factor IXa by co-operative maturation of the substrate-binding site. The Biochemical journal 473, 2395-2411.

  • Krisch, L.M., Posselt, G., Hammerl, P., and Wessler, S. (2016). CagA Phosphorylation in Helicobacter pylori-Infected B Cells Is Mediated by the Nonreceptor Tyrosine Kinases of the Src and Abl Families. Infection and immunity 84, 2671-2680.

  • Krenn, P.W., Hofbauer, S.W., Pucher, S., Hutterer, E., Hinterseer, E., Denk, U., Asslaber, D., Ganghammer, S., Sternberg, C., Neureiter, D., Aberger, F., Wickstrom, S.A., Egle, A., Greil, R., and Hartmann, T.N. (2016). ILK Induction in Lymphoid Organs by a TNFalpha-NF-kappaB-Regulated Pathway Promotes the Development of Chronic Lymphocytic Leukemia. Cancer research 76, 2186-2196.

  • Kollek, M., Muller, A., Egle, A., and Erlacher, M. (2016). Bcl-2 proteins in development, health, and disease of the hematopoietic system. The FEBS journal 283, 2779-2810.

  • Kocher, T., Asslaber, D., Zaborsky, N., Flenady, S., Denk, U., Reinthaler, P., Ablinger, M., Geisberger, R., Bauer, J.W., Seiffert, M., Hartmann, T.N., Greil, R., Egle, A., and Pinon Hofbauer, J. (2016). CD4+ T cells, but not non-classical monocytes, are dispensable for the development of chronic lymphocytic leukemia in the TCL1-tg murine model. Leukemia 30, 1409-1413.

  • Klieser, E., Swierczynski, S., Mayr, C., Jager, T., Schmidt, J., Neureiter, D., Kiesslich, T., and Illig, R. (2016a). Differential role of Hedgehog signaling in human pancreatic (patho-) physiology: An up to date review. World J Gastrointest Pathophysiol 7, 199-210.

  • Klieser, E., Pichelstorfer, M., Weyland, D., Kemmerling, R., Swierczynski, S., Dinnewitzer, A., Jager, T., Kiesslich, T., Neureiter, D., and Illig, R. (2016b). Back to the start: Evaluation of prognostic markers in gastrointestinal stromal tumors. Molecular and clinical oncology 4, 763-773.

  • Khankari, N.K., Shu, X.O., Wen, W., Kraft, P., Lindstrom, S., Peters, U., Schildkraut, J., Schumacher, F., Bofetta, P., Risch, A., Bickeboller, H., Amos, C.I., Easton, D., Eeles, R.A., Gruber, S.B., Haiman, C.A., Hunter, D.J., Chanock, S.J., Pierce, B.L., Zheng, W., Colorectal Transdisciplinary, S., Discovery, B., Risk of Inherited Variants in Breast, C., Elucidating Loci Involved in Prostate Cancer, S., and Transdisciplinary Research in Cancer of the, L. (2016). Association between Adult Height and Risk of Colorectal, Lung, and Prostate Cancer: Results from Meta-analyses of Prospective Studies and Mendelian Randomization Analyses. PLoS Med 13, e1002118.

  • Keller, M., Kuhn, K.K., Einsiedel, J., Hubner, H., Biselli, S., Mollereau, C., Wifling, D., Svobodova, J., Bernhardt, G., Cabrele, C., Vanderheyden, P.M., Gmeiner, P., and Buschauer, A. (2016). Mimicking of Arginine by Functionalized N(omega)-Carbamoylated Arginine As a New Broadly Applicable Approach to Labeled Bioactive Peptides: High Affinity Angiotensin, Neuropeptide Y, Neuropeptide FF, and Neurotensin Receptor Ligands As Examples. Journal of medicinal chemistry 59, 1925-1945.

  • Karthaus, M., Hofheinz, R.D., Mineur, L., Letocha, H., Greil, R., Thaler, J., Fernebro, E., Oliner, K.S., Boedigheimer, M., Twomey, B., Zhang, Y., Demonty, G., and Kohne, C.H. (2016). Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer. British journal of cancer 115, 1215-1222.

  • Karami, S., Han, Y., Pande, M., Cheng, I., Rudd, J., Pierce, B.L., Nutter, E.L., Schumacher, F.R., Kote-Jarai, Z., Lindstrom, S., Witte, J.S., Fang, S., Han, J., Kraft, P., Hunter, D.J., Song, F., Hung, R.J., McKay, J., Gruber, S.B., Chanock, S.J., Risch, A., Shen, H., Haiman, C.A., Boardman, L., Ulrich, C.M., Casey, G., Peters, U., Amin Al Olama, A., Berchuck, A., Berndt, S.I., Bezieau, S., Brennan, P., Brenner, H., Brinton, L., Caporaso, N., Chan, A.T., Chang-Claude, J., Christiani, D.C., Cunningham, J.M., Easton, D., Eeles, R.A., Eisen, T., Gala, M., Gallinger, S.J., Gayther, S.A., Goode, E.L., Gronberg, H., Henderson, B.E., Houlston, R., Joshi, A.D., Kury, S., Landi, M.T., Le Marchand, L., Muir, K., Newcomb, P.A., Permuth-Wey, J., Pharoah, P., Phelan, C., Potter, J.D., Ramus, S.J., Risch, H., Schildkraut, J., Slattery, M.L., Song, H., Wentzensen, N., White, E., Wiklund, F., Zanke, B.W., Sellers, T.A., Zheng, W., Chatterjee, N., Amos, C.I., Doherty, J.A., Gecco, the Game-On Network: Corect, D.E.F., and Tricl (2016). Telomere structure and maintenance gene variants and risk of five cancer types. International journal of cancer Journal international du cancer 139, 2655-2670.

  • Kang, X., Liu, H., Onaitis, M.W., Liu, Z., Owzar, K., Han, Y., Su, L., Wei, Y., Hung, R.J., Brhane, Y., McLaughlin, J., Brennan, P., Bickeboller, H., Rosenberger, A., Houlston, R.S., Caporaso, N., Landi, M.T., Heinrich, J., Risch, A., Wu, X., Ye, Y., Christiani, D.C., Amos, C.I., Wei, Q., and Transdisciplinary Research in Cancer of the Lung Research, T. (2016). Polymorphisms of the centrosomal gene (FGFR1OP) and lung cancer risk: a meta-analysis of 14,463 cases and 44,188 controls. Carcinogenesis 37, 280-289.

  • Hofbauer, S.W., Krenn, P.W., Pinomicronn Hofbauer, J., Pucher, S., Asslaber, D., Egle, A., Hartmann, T.N., and Greil, R. (2016). The AKT1 isoform plays a dominant role in the survival and chemoresistance of chronic lymphocytic leukaemia cells. British journal of haematology 172, 815-819.

  • Hanna, B.S., McClanahan, F., Yazdanparast, H., Zaborsky, N., Kalter, V., Rossner, P.M., Benner, A., Durr, C., Egle, A., Gribben, J.G., Lichter, P., and Seiffert, M. (2016). Depletion of CLL-associated patrolling monocytes and macrophages controls disease development and repairs immune dysfunction in vivo. Leukemia 30, 570-579.

  • Haider, M., Ji, B., Haselgrubler, T., Sonnleitner, A., Aberger, F., and Hesse, J. (2016a). A microfluidic multiwell chip for enzyme-free detection of mRNA from few cells. Biosens Bioelectron 86, 20-26.

  • Haider, M., Haselgrubler, T., Sonnleitner, A., Aberger, F., and Hesse, J. (2016b). A Double-Hybridization Approach for the Transcription- and Amplification-Free Detection of Specific mRNA on a Microarray. Microarrays (Basel) 5.

  • Haerzschel, A., Catusse, J., Hutterer, E., Paunovic, M., Zirlik, K., Eibel, H., Krenn, P.W., Hartmann, T.N., and Burger, M. (2016). BCR and chemokine responses upon anti-IgM and anti-IgD stimulation in chronic lymphocytic leukaemia. Annals of hematology 95, 1979-1988.

  • Guo, S., Skala, W., Magdolen, V., Briza, P., Biniossek, M.L., Schilling, O., Kellermann, J., Brandstetter, H., and Goettig, P. (2016). A Single Glycan at the 99-Loop of Human Kallikrein-related Peptidase 2 Regulates Activation and Enzymatic Activity. The Journal of biological chemistry 291, 593-604.

  • Gruber, W., Hutzinger, M., Elmer, D.P., Parigger, T., Sternberg, C., Cegielkowski, L., Zaja, M., Leban, J., Michel, S., Hamm, S., Vitt, D., and Aberger, F. (2016). DYRK1B as therapeutic target in Hedgehog/GLI-dependent cancer cells with Smoothened inhibitor resistance. Oncotarget 7, 7134-7148.

  • Greil, R., Obrtlikova, P., Smolej, L., Kozak, T., Steurer, M., Andel, J., Burgstaller, S., Mikuskova, E., Gercheva, L., Nosslinger, T., Papajik, T., Ladicka, M., Girschikofsky, M., Hrubisko, M., Jager, U., Fridrik, M., Pecherstorfer, M., Kralikova, E., Burcoveanu, C., Spasov, E., Petzer, A., Mihaylov, G., Raynov, J., Oexle, H., Zabernigg, A., Flochova, E., Palasthy, S., Stehlikova, O., Doubek, M., Altenhofer, P., Pleyer, L., Melchardt, T., Klingler, A., Mayer, J., and Egle, A. (2016). Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematol 3, e317-329.

  • Ganghammer, S., Gutjahr, J., Hutterer, E., Krenn, P.W., Pucher, S., Zelle-Rieser, C., Johrer, K., Wijtmans, M., Leurs, R., Smit, M.J., Gattei, V., Greil, R., and Hartmann, T.N. (2016). Combined CXCR3/CXCR4 measurements are of high prognostic value in chronic lymphocytic leukemia due to negative co-operativity of the receptors. Haematologica 101, e99-102.

  • Gampenrieder, S.P., Rinnerthaler, G., and Greil, R. (2016a). CDK4/6 inhibition in luminal breast cancer. Memo 9, 76-81.

  • Gampenrieder, S.P., Hufnagl, C., Brechelmacher, S., Huemer, F., Hackl, H., Rinnerthaler, G., Romeder, F., Monzo Fuentes, C., Morre, P., Hauser-Kronberger, C., Mlineritsch, B., and Greil, R. (2016b). Endothelin-1 genetic polymorphism as predictive marker for bevacizumab in metastatic breast cancer. Pharmacogenomics J.

  • Fridrik, M.A., Jaeger, U., Petzer, A., Willenbacher, W., Keil, F., Lang, A., Andel, J., Burgstaller, S., Krieger, O., Oberaigner, W., Sihorsch, K., and Greil, R. (2016). Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentose Tumortherapie AGMT](NHL-14). Eur J Cancer 58, 112-121.

  • Foukakis, T., von Minckwitz, G., Bengtsson, N.O., Brandberg, Y., Wallberg, B., Fornander, T., Mlineritsch, B., Schmatloch, S., Singer, C.F., Steger, G., Egle, D., Karlsson, E., Carlsson, L., Loibl, S., Untch, M., Hellstrom, M., Johansson, H., Anderson, H., Malmstrom, P., Gnant, M., Greil, R., Mobus, V., Bergh, J., Swedish Breast Cancer Group, t.G.B.G., the Austrian, B., and Colorectal Cancer Study, G. (2016). Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial. JAMA 316, 1888-1896.

  • Fehringer, G., Kraft, P., Pharoah, P.D., Eeles, R.A., Chatterjee, N., Schumacher, F.R., Schildkraut, J.M., Lindstrom, S., Brennan, P., Bickeboller, H., Houlston, R.S., Landi, M.T., Caporaso, N., Risch, A., Amin Al Olama, A., Berndt, S.I., Giovannucci, E.L., Gronberg, H., Kote-Jarai, Z., Ma, J., Muir, K., Stampfer, M.J., Stevens, V.L., Wiklund, F., Willett, W.C., Goode, E.L., Permuth, J.B., Risch, H.A., Reid, B.M., Bezieau, S., Brenner, H., Chan, A.T., Chang-Claude, J., Hudson, T.J., Kocarnik, J.K., Newcomb, P.A., Schoen, R.E., Slattery, M.L., White, E., Adank, M.A., Ahsan, H., Aittomaki, K., Baglietto, L., Blomquist, C., Canzian, F., Czene, K., Dos-Santos-Silva, I., Eliassen, A.H., Figueroa, J.D., Flesch-Janys, D., Fletcher, O., Garcia-Closas, M., Gaudet, M.M., Johnson, N., Hall, P., Hazra, A., Hein, R., Hofman, A., Hopper, J.L., Irwanto, A., Johansson, M., Kaaks, R., Kibriya, M.G., Lichtner, P., Liu, J., Lund, E., Makalic, E., Meindl, A., Muller-Myhsok, B., Muranen, T.A., Nevanlinna, H., Peeters, P.H., Peto, J., Prentice, R.L., Rahman, N., Sanchez, M.J., Schmidt, D.F., Schmutzler, R.K., Southey, M.C., Tamimi, R., Travis, R.C., Turnbull, C., Uitterlinden, A.G., Wang, Z., Whittemore, A.S., Yang, X.R., Zheng, W., Buchanan, D.D., Casey, G., Conti, D.V., Edlund, C.K., Gallinger, S., Haile, R.W., Jenkins, M., Le Marchand, L., Li, L., Lindor, N.M., Schmit, S.L., Thibodeau, S.N., Woods, M.O., Rafnar, T., Gudmundsson, J., Stacey, S.N., Stefansson, K., Sulem, P., Chen, Y.A., Tyrer, J.P., Christiani, D.C., Wei, Y., Shen, H., Hu, Z., Shu, X.O., Shiraishi, K., Takahashi, A., Bosse, Y., Obeidat, M., Nickle, D., Timens, W., Freedman, M.L., Li, Q., Seminara, D., Chanock, S.J., Gong, J., Peters, U., Gruber, S.B., Amos, C.I., Sellers, T.A., Easton, D.F., Hunter, D.J., Haiman, C.A., Henderson, B.E., Hung, R.J., Ovarian Cancer Association, C., Consortium, P., Hereditary, B., Ovarian Cancer Research Group, N., Colorectal Transdisciplinary, S., African American Breast Cancer, C., and African Ancestry Prostate Cancer, C. (2016). Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations. Cancer research 76, 5103-5114.

  • Di Fazio, P., Waldegger, P., Jabari, S., Lingelbach, S., Montalbano, R., Ocker, M., Slater, E.P., Bartsch, D.K., Illig, R., Neureiter, D., and Wissniowski, T.T. (2016). Autophagy-related cell death by pan-histone deacetylase inhibition in liver cancer. Oncotarget 7, 28998-29010.

  • Debela, M., Magdolen, V., Bode, W., Brandstetter, H., and Goettig, P. (2016). Structural basis for the Zn2+ inhibition of the zymogen-like kallikrein-related peptidase 10. Biological chemistry 397, 1251-1264.

  • Daud, A.I., Loo, K., Pauli, M.L., Sanchez-Rodriguez, R., Sandoval, P.M., Taravati, K., Tsai, K., Nosrati, A., Nardo, L., Alvarado, M.D., Algazi, A.P., Pampaloni, M.H., Lobach, I.V., Hwang, J., Pierce, R.H., Gratz, I.K., Krummel, M.F., and Rosenblum, M.D. (2016). Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. The Journal of clinical investigation 126, 3447-3452.

  • Dall, E., and Brandstetter, H. (2016). Structure and function of legumain in health and disease. Biochimie 122, 126-150.

  • Dahms, S.O., Creemers, J.W., Schaub, Y., Bourenkov, G.P., Zogg, T., Brandstetter, H., and Than, M.E. (2016). The structure of a furin-antibody complex explains non-competitive inhibition by steric exclusion of substrate conformers. Sci Rep 6, 34303.

  • Chen, L.S., Baker, T., Hung, R.J., Horton, A., Culverhouse, R., Hartz, S., Saccone, N., Cheng, I., Deng, B., Han, Y., Hansen, H.M., Horsman, J., Kim, C., Rosenberger, A., Aben, K.K., Andrew, A.S., Chang, S.C., Saum, K.U., Dienemann, H., Hatsukami, D.K., Johnson, E.O., Pande, M., Wrensch, M.R., McLaughlin, J., Skaug, V., van der Heijden, E.H., Wampfler, J., Wenzlaff, A., Woll, P., Zienolddiny, S., Bickeboller, H., Brenner, H., Duell, E.J., Haugen, A., Bruske, I., Kiemeney, L.A., Lazarus, P., Le Marchand, L., Liu, G., Mayordomo, J., Risch, A., Schwartz, A.G., Teare, M.D., Wu, X., Wiencke, J.K., Yang, P., Zhang, Z.F., Spitz, M.R., Amos, C.I., and Bierut, L.J. (2016). Genetic Risk Can Be Decreased: Quitting Smoking Decreases and Delays Lung Cancer for Smokers With High and Low CHRNA5 Risk Genotypes - A Meta-Analysis. EBioMedicine 11, 219-226.

  • Cabrele, C., and Reiser, O. (2016). The Modern Face of Synthetic Heterocyclic Chemistry. J Org Chem 81, 10109-10125.

  • Boyles, M.S., Ranninger, C., Reischl, R., Rurik, M., Tessadri, R., Kohlbacher, O., Duschl, A., and Huber, C.G. (2016). Copper oxide nanoparticle toxicity profiling using untargeted metabolomics. Part Fibre Toxicol 13, 49.

  • Boll, B., Goergen, H., Behringer, K., Brockelmann, P.J., Hitz, F., Kerkhoff, A., Greil, R., von Tresckow, B., Eichenauer, D.A., Burkle, C., Borchmann, S., Fuchs, M., Diehl, V., Engert, A., and Borchmann, P. (2016). Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood 127, 2189-2192.

  • Boige, V., Vincent, M., Alexandre, P., Tejpar, S., Landolfi, S., Le Malicot, K., Greil, R., Cuyle, P.J., Yilmaz, M., Faroux, R., Matzdorff, A., Salazar, R., Lepage, C., Taieb, J., and Laurent-Puig, P. (2016). DPYD Genotyping to Predict Adverse Events Following Treatment With Flourouracil-Based Adjuvant Chemotherapy in Patients With Stage III Colon Cancer: A Secondary Analysis of the PETACC-8 Randomized Clinical Trial. JAMA Oncol.

  • Benedetti, D., Tissino, E., Caldana, C., Dal Bo, M., Bomben, R., Marconi, D., Ganghammer, S., Zaja, F., Pozzato, G., Di Raimondo, F., Hartmann, T.N., Del Poeta, G., VanMeter, A., Zucchetto, A., Espina, V., Liotta, L., and Gattei, V. (2016). Persistent CD49d engagement in circulating CLL cells: a role for blood-borne ligands? Leukemia 30, 513-517.

  • Behringer, K., Goergen, H., Muller, H., Thielen, I., Brillant, C., Kreissl, S., Halbsguth, T.V., Meissner, J., Greil, R., Moosmann, P., Shonukan, O., Rueffer, J.U., Flechtner, H.H., Fuchs, M., Diehl, V., Engert, A., and Borchmann, P. (2016). Cancer-Related Fatigue in Patients With and Survivors of Hodgkin Lymphoma: The Impact on Treatment Outcome and Social Reintegration. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 34, 4329-4337.

  • Behmuller, R., Kavkova, E., Duh, S., Huber, C.G., and Tenhaken, R. (2016). The role of arabinokinase in arabinose toxicity in plants. Plant J 87, 376-390.

  • Behm, B., Di Fazio, P., Michl, P., Neureiter, D., Kemmerling, R., Hahn, E.G., Strobel, D., Gress, T., Schuppan, D., and Wissniowski, T.T. (2016). Additive antitumour response to the rabbit VX2 hepatoma by combined radio frequency ablation and toll like receptor 9 stimulation. Gut 65, 134-143.

  • Abfalter, C.M., Schubert, M., Gotz, C., Schmidt, T.P., Posselt, G., and Wessler, S. (2016a). HtrA-mediated E-cadherin cleavage is limited to DegP and DegQ homologs expressed by gram-negative pathogens. Cell communication and signaling : CCS 14, 30.

  • Abfalter, C.M., Schonauer, E., Ponnuraj, K., Huemer, M., Gadermaier, G., Regl, C., Briza, P., Ferreira, F., Huber, C.G., Brandstetter, H., Posselt, G., and Wessler, S. (2016b). Cloning, Purification and Characterization of the Collagenase ColA Expressed by Bacillus cereus ATCC 14579. PloS one 11, e0162433.

  • Zhang C, Doherty JA, Burgess S, Hung RJ, Lindstrom S, Kraft P, Gong J, Amos CI, Sellers TA, Monteiro AN, et al: Genetic determinants of telomere length and risk of common cancers: a Mendelian randomization study. Human molecular genetics 2015.

  • Wrage M, Hagmann W, Kemming D, Uzunoglu FG, Riethdorf S, Effenberger K, Westphal M, Lamszus K, Kim SZ, Becker N, et al: Identification of HERC5 and its potential role in NSCLC progression. International journal of cancer Journal international du cancer 2015, 136:2264-2272.

  • Wolkerstorfer S, Schwaiger E, Rinnerthaler M, Karina Gratz I, Zoegg T, Brandstetter H, Achatz-Straussberger G: HAX1 deletion impairs BCR internalization and leads to delayed BCR-mediated apoptosis. Cell Mol Immunol 2015.

  • Troppan KT, Melchardt T, Deutsch A, Schlick K, Stojakovic T, Bullock MD, Reitz D, Beham-Schmid C, Weiss L, Neureiter D, et al: The significance of pre-treatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: A dual-center study in diffuse large B-cell lymphoma patients. Eur J Haematol 2015.

  • Tiede A, Klamroth R, Scharf RE, Trappe RU, Holstein K, Huth-Kuhne A, Gottstein S, Geisen U, Schenk J, Scholz U, et al: Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study. Blood 2015, 125:1091-1097.

  • Sochalska M, Tuzlak S, Egle A, Villunger A: Lessons from gain- and loss-of-function models of pro-survival Bcl2 family proteins: implications for targeted therapy. The FEBS journal 2015, 282:834-849.

  • Shalapour S, Font-Burgada J, Di Caro G, Zhong Z, Sanchez-Lopez E, Dhar D, Willimsky G, Ammirante M, Strasner A, Hansel DE, et al: Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy. Nature 2015, 521:94-98.

  • Schutz A, Roser K, Klitzsch J, Lieder F, Aberger F, Gruber W, Mueller KM, Pupyshev A, Moriggl R, Friedrich K: Lung Adenocarcinomas and Lung Cancer Cell Lines Show Association of MMP-1 Expression With STAT3 Activation. Translational oncology 2015, 8:97-105.

  • Schultz L, Zurich MG, Culot M, da Costa A, Landry C, Bellwon P, Kristl T, Hormann K, Ruzek S, Aiche S, et al: Evaluation of drug-induced neurotoxicity based on metabolomics, proteomics and electrical activity measurements in complementary CNS in vitro models. Toxicol In Vitro 2015.

  • Schmidt A, Denier N, Magon S, Radue EW, Huber CG, Riecher-Rossler A, Wiesbeck GA, Lang UE, Borgwardt S, Walter M: Increased functional connectivity in the resting-state basal ganglia network after acute heroin substitution. Transl Psychiatry 2015, 5:e533.

  • Schlick K, Troch M, Placher-Sorko G, Faber V, Neureiter D, Berghoff AS, Preusser M, Greil R, Hopfinger G: A patient diagnosed with BRAF-mutated non-small cell lung cancer and hairy cell leukemia: at last, which entity is really carrying the BRAF mutation? Annals of hematology 2015, 94:345-346.

  • Schiefer AI, Vesely P, Hassler MR, Egger G, Kenner L: The role of AP-1 and epigenetics in ALCL. Front Biosci (Schol Ed) 2015, 7:226-235.

  • Rauch I, Rosebrock F, Hainzl E, Heider S, Majoros A, Wienerroither S, Strobl B, Stockinger S, Kenner L, Muller M, Decker T: Noncanonical Effects of IRF9 in Intestinal Inflammation: More than Type I and Type III Interferons. Mol Cell Biol 2015, 35:2332-2343.

  • Ranninger C, Rurik M, Limonciel A, Ruzek S, Reischl R, Wilmes A, Jennings P, Hewitt P, Dekant W, Kohlbacher O, Huber CG: Nephron Toxicity Profiling via Untargeted Metabolome Analysis Employing a High Performance Liquid Chromatography-Mass Spectrometry-based Experimental and Computational Pipeline. The Journal of biological chemistry 2015, 290:19121-19132.

  • Ramos F, Thepot S, Pleyer L, Maurillo L, Itzykson R, Bargay J, Stauder R, Venditti A, Seegers V, Martinez-Robles V, et al: Azacitidine frontline therapy for unfit acute myeloid leukemia patients: Clinical use and outcome prediction. Leukemia research 2015, 39:296-306.

  • Poirier JG, Brennan P, McKay JD, Spitz MR, Bickeboller H, Risch A, Liu G, Le Marchand L, Tworoger S, McLaughlin J, et al: Informed Genome-Wide Association Analysis With Family History As a Secondary Phenotype Identifies Novel Loci of Lung Cancer. Genetic epidemiology 2015.

  • Pleyer L, Greil R: Digging deep into "dirty" drugs - modulation of the methylation machinery. Drug Metab Rev 2015:1-28.

  • Pircher M, Mlineritsch B, Fridrik MA, Dittrich C, Lang A, Petru E, Weltermann A, Thaler J, Hufnagl C, Gampenrieder SP, et al: Lapatinib-plus-pegylated liposomal doxorubicin in advanced HER2-positive breast cancer following trastuzumab: a phase II trial. Anticancer research 2015, 35:517-521.

  • Perna AM, Rodrigues T, Schmidt TP, Bohm M, Stutz K, Reker D, Pfeiffer B, Altmann KH, Backert S, Wessler S, Schneider G: Fragment-Based De Novo Design Reveals a Small-Molecule Inhibitor of Helicobacter Pylori HtrA. Angewandte Chemie 2015, 54:10244-10248.

  • Pencik J, Schlederer M, Gruber W, Unger C, Walker SM, Chalaris A, Marie IJ, Hassler MR, Javaheri T, Aksoy O, et al: STAT3 regulated ARF expression suppresses prostate cancer metastasis. Nature communications 2015, 6:7736.

  • Pathria P, Gotthardt D, Prchal-Murphy M, Putz EM, Holcmann M, Schlederer M, Grabner B, Crncec I, Svinka J, Musteanu M, et al: Myeloid promotes formation of colitis-associated colorectal cancer in mice. Oncoimmunology 2015, 4:e998529.

  • Park J, Schlederer M, Schreiber M, Ice R, Merkel O, Bilban M, Hofbauer S, Kim S, Addison J, Zou J, et al: AF1q is a novel TCF7 co-factor which activates CD44 and promotes breast cancer metastasis. Oncotarget 2015.

  • Nivarthi H, Prchal-Murphy M, Swoboda A, Hager M, Schlederer M, Kenner L, Tuckermann J, Sexl V, Moriggl R, Ermakova O: Stat5 gene dosage in T cells modulates CD8+ T-cell homeostasis and attenuates contact hypersensitivity response in mice. Allergy 2015, 70:67-79.

  • Moti N, Malcolm T, Hamoudi R, Mian S, Garland G, Hook CE, Burke GA, Wasik MA, Merkel O, Kenner L, et al: Anaplastic large cell lymphoma-propagating cells are detectable by side population analysis and possess an expression profile reflective of a primitive origin. Oncogene 2015, 34:1843-1852.

  • Merkel O, Hamacher F, Griessl R, Grabner L, Schiefer AI, Prutsch N, Baer C, Egger G, Schlederer M, Krenn PW, et al: Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation. The Journal of pathology 2015, 236:445-456.

  • Melchardt T, Weiss L, Hufnagl C, Neureiter D, Kemmerling R, Morre P, Boekstegers A, Hopfinger G, Auberger J, Steinkirchner S, et al: Treatment of aggressive B-cell lymphoma in elderly patients: influence of single nucleotide polymorphisms affecting pharmacodynamics of chemotherapeutics. Leukemia & lymphoma 2015, 56:353-360.

  • Melchardt T, Troppan K, Weiss L, Hufnagl C, Neureiter D, Trankenschuh W, Hopfinger G, Magnes T, Deutsch A, Neumeister P, et al: A modified scoring of the NCCN-IPI is more accurate in the elderly and is improved by albumin and beta2 -microglobulin. British journal of haematology 2015, 168:239-245.

  • Mayr C, Neureiter D, Wagner A, Pichler M, Kiesslich T: The role of polycomb repressive complexes in biliary tract cancer. Expert opinion on therapeutic targets 2015, 19:363-375.

  • Mathieu R, Klatte T, Lucca I, Beutcha AM, Seitz C, Karakiewicz PI, Fajkovic H, Sun M, Lotan Y, Scherr DS, et al: Prognostic value of Caveolin-1 in patients treated with radical prostatectomy: a multicentric validation study. BJU Int 2015.

  • Kiss I, Unger C, Huu CN, Atanasov AG, Kramer N, Chatruphonprasert W, Brenner S, McKinnon R, Peschel A, Vasas A, et al: Lobatin B inhibits NPM/ALK and NF-kappaB attenuating anaplastic-large-cell-lymphomagenesis and lymphendothelial tumour intravasation. Cancer letters 2015, 356:994-1006.

  • Kern D, Regl G, Hofbauer SW, Altenhofer P, Achatz G, Dlugosz A, Schnidar H, Greil R, Hartmann TN, Aberger F: Hedgehog/GLI and PI3K signaling in the initiation and maintenance of chronic lymphocytic leukemia. Oncogene 2015.

  • Johrer K, Ploner C, Thangavadivel S, Wuggenig P, Greil R: Adipocyte-derived players in hematologic tumors: useful novel targets? Expert Opin Biol Ther 2015, 15:61-77.

  • Hinterseer E, Stiefel O, Neureiter D, Kandler G, Vogt S, Hutter J, Strasser G, Greil R, Hartmann TN, Hopfinger G: VLA-4 and CXCR4 overexpression in bone marrow of an aleukemic B-cell acute lymphoblastic leukemia presenting with osteolytic bone lesions. Leukemia & lymphoma 2015:1-3.

  • Grabner B, Schramek D, Mueller KM, Moll HP, Svinka J, Hoffmann T, Bauer E, Blaas L, Hruschka N, Zboray K, et al: Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis. Nature communications 2015, 6:6285.

  • Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Knauer M, Moik M, Jakesz R, Seifert M, Taucher S, Bjelic-Radisic V, et al: Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2015, 26:313-320.

  • Fastner G, Reitsamer R, Ziegler I, Zehentmayr F, Fussl C, Kopp P, Peintinger F, Greil R, Fischer T, Deutschmann H, Sedlmayer F: IOERT as anticipated tumor bed boost during breast-conserving surgery after neoadjuvant chemotherapy in locally advanced breast cancer--results of a case series after 5-year follow-up. International journal of cancer Journal international du cancer 2015, 136:1193-1201.

  • Fastner G, Reitsamer R, Ziegler I, Zehentmayr F, Fussl C, Kopp P, Peintinger F, Greil R, Fischer T, Deutschmann H, Sedlmayer F: IOERT as anticipated tumor bed boost during breast-conserving surgery after neoadjuvant chemotherapy in locally advanced breast cancer-Results of a case series after 5-year follow-up. International journal of cancer Journal international du cancer 2015, 136:1193-1201.

  • Engelmann JC, Amann T, Ott-Rotzer B, Nutzel M, Reinders Y, Reinders J, Thasler WE, Kristl T, Teufel A, Huber CG, et al: Causal Modeling of Cancer-Stromal Communication Identifies PAPPA as a Novel Stroma-Secreted Factor Activating NFkappaB Signaling in Hepatocellular Carcinoma. PLoS Comput Biol 2015, 11:e1004293.

  • Dueregger A, Schopf B, Eder T, Hofer J, Gnaiger E, Aufinger A, Kenner L, Perktold B, Ramoner R, Klocker H, Eder IE: Differential Utilization of Dietary Fatty Acids in Benign and Malignant Cells of the Prostate. PloS one 2015, 10:e0135704.

  • Dall E, Fegg JC, Briza P, Brandstetter H: Structure and mechanism of an aspartimide-dependent Peptide ligase in human legumain. Angewandte Chemie 2015, 54:2917-2921.

  • Crescenzo R, Abate F, Lasorsa E, Tabbo F, Gaudiano M, Chiesa N, Di Giacomo F, Spaccarotella E, Barbarossa L, Ercole E, et al: Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. Cancer cell 2015, 27:516-532.

  • Chen LS, Hung RJ, Baker T, Horton A, Culverhouse R, Saccone N, Cheng I, Deng B, Han Y, Hansen HM, et al: CHRNA5 risk variant predicts delayed smoking cessation and earlier lung cancer diagnosis--a meta-analysis. Journal of the National Cancer Institute 2015, 107.

  • Burgstaller S, Bettelheim P, Krieger O, Machherndl-Spandl S, Nosslinger T, Pleyer L, Sill H, Sperr WR, Stauder R, Valent P, Pfeilstocker M: 10th anniversary of the Austrian MDS Platform: aims and ongoing projects. Wiener klinische Wochenschrift 2015, 127:12-15.

  • Blank PR, Filipits M, Dubsky P, Gutzwiller F, Lux MP, Brase JC, Weber KE, Rudas M, Greil R, Loibl S, et al: Cost-effectiveness analysis of prognostic gene expression signature-based stratification of early breast cancer patients. Pharmacoeconomics 2015, 33:179-190.

  • Birner P, Egger G, Merkel O, Kenner L: JunB and PTEN in prostate cancer: 'loss is nothing else than change'. Cell death and differentiation 2015, 22:522-523.

  • Aiche S, Sachsenberg T, Kenar E, Walzer M, Wiswedel B, Kristl T, Boyles M, Duschl A, Huber CG, Berthold MR, et al: Workflows for automated downstream data analysis and visualization in large-scale computational mass spectrometry. Proteomics 2015.

  • Wagner A, Denzer UW, Neureiter D, Kiesslich T, Puespoeck A, Rauws EA, Emmanuel K, Degenhardt N, Frick U, Beuers U, et al: Temoporfin improves efficacy of photodynamic therapy in advanced biliary tract carcinoma: A multicenter prospective phase II study. Hepatology 2015.

  • Troppan KT, Melchardt T, Deutsch A, Schlick K, Stojakovic T, Bullock MD, Reitz D, Beham-Schmid C, Weiss L, Neureiter D, et al: The significance of pretreatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patients. Eur J Haematol 2015.

  • Swierczynski S, Klieser E, Illig R, Alinger-Scharinger B, Kiesslich T, Neureiter D: Histone deacetylation meets miRNA: epigenetics and post-transcriptional regulation in cancer and chronic diseases. Expert Opin Biol Ther 2015, 15:651-664.

  • Stintzing S, Zhang W, Heinemann V, Neureiter D, Kemmerling R, Kirchner T, Jung A, Folwaczny M, Yang D, Ning Y, et al: Polymorphisms in genes involved in EGFR-turnover are predictive for cetuximab efficacy in colorectal cancer. Molecular cancer therapeutics 2015.

  • Schlick K, Troch M, Placher-Sorko G, Faber V, Neureiter D, Berghoff AS, Preusser M, Greil R, Hopfinger G: A patient diagnosed with BRAF-mutated non-small cell lung cancer and hairy cell leukemia: at last, which entity is really carrying the BRAF mutation? Annals of hematology 2015, 94:345-346.

  • Morscher RJ, Aminzadeh-Gohari S, Feichtinger RG, Mayr JA, Lang R, Neureiter D, Sperl W, Kofler B: Inhibition of Neuroblastoma Tumor Growth by Ketogenic Diet and/or Calorie Restriction in a CD1-Nu Mouse Model. PloS one 2015, 10:e0129802.

  • Menendez-Castro C, Cordasic N, Neureiter D, Amann K, Marek I, Volkert G, Stintzing S, Jahn A, Rascher W, Hilgers KF, Hartner A: Under-expression of alpha8 integrin aggravates experimental atherosclerosis. The Journal of pathology 2015, 236:5-16.

  • Melchardt T, Weiss L, Hufnagl C, Neureiter D, Kemmerling R, Morre P, Boekstegers A, Hopfinger G, Auberger J, Steinkirchner S, et al: Treatment of aggressive B-cell lymphoma in elderly patients: influence of single nucleotide polymorphisms affecting pharmacodynamics of chemotherapeutics. Leukemia & lymphoma 2015, 56:353-360.

  • Melchardt T, Troppan K, Weiss L, Hufnagl C, Neureiter D, Trankenschuh W, Hopfinger G, Magnes T, Deutsch A, Neumeister P, et al: A modified scoring of the NCCN-IPI is more accurate in the elderly and is improved by albumin and beta2 -microglobulin. British journal of haematology 2015, 168:239-245.

  • Mayr C, Wagner A, Stoecklinger A, Jakab M, Illig R, Berr F, Pichler M, P DIF, Ocker M, Neureiter D, Kiesslich T: 3-Deazaneplanocin A May Directly Target Putative Cancer Stem Cells in Biliary Tract Cancer. Anticancer research 2015, 35:4697-4705.

  • Mayr C, Wagner A, Neureiter D, Pichler M, Jakab M, Illig R, Berr F, Kiesslich T: The green tea catechin epigallocatechin gallate induces cell cycle arrest and shows potential synergism with cisplatin in biliary tract cancer cells. BMC Complement Altern Med 2015, 15:194.

  • Mayr C, Neureiter D, Wagner A, Pichler M, Kiesslich T: The role of polycomb repressive complexes in biliary tract cancer. Expert opinion on therapeutic targets 2015, 19:363-375.

  • Mayr C, Neureiter D, Pichler M, Berr F, Wagner A, Kiesslich T, Namberger K: Cytotoxic effects of chemokine receptor 4 inhibition by AMD3100 in biliary tract cancer cells: Potential drug synergism with gemcitabine. Mol Med Rep 2015, 12:2247-2252.

  • Hinterseer E, Stiefel O, Neureiter D, Kandler G, Vogt S, Hutter J, Strasser G, Greil R, Hartmann TN, Hopfinger G: VLA-4 and CXCR4 overexpression in bone marrow of an aleukemic B-cell acute lymphoblastic leukemia presenting with osteolytic bone lesions. Leukemia & lymphoma 2015:1-3.

  • Henrici A, Montalbano R, Neureiter D, Krause M, Stiewe T, Slater EP, Quint K, Ocker M, Di Fazio P: The pan-deacetylase inhibitor panobinostat suppresses the expression of oncogenic miRNAs in hepatocellular carcinoma cell lines. Molecular carcinogenesis 2015, 54:585-597.

  • Gahr S, Mayr C, Kiesslich T, Illig R, Neureiter D, Alinger B, Ganslmayer M, Wissniowski T, Fazio PD, Montalbano R, et al: The pan-deacetylase inhibitor panobinostat affects angiogenesis in hepatocellular carcinoma models via modulation of CTGF expression. International journal of oncology 2015, 47:963-970.

© 2020 Cancer Cluster Salzburg

  • Facebook

supported by